Samdeep K. Mouli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Samdeep K. Mouli has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Riad Salem
Department of Radiology, Section of Vascular and Interventional Radiology, Northwestern University, Chicago, USA
8 shared publications Riad Salem
Section of Interventional Radiology, Department of Radiology, Northwestern Feinberg School of Medicine, Chicago, Illinois
4 shared publications- Ahmed Gabr
Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA
2 shared publications - Ahsun Riaz
Division of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
2 shared publications Ajay K. Varadhan
Section of Interventional Radiology, Department of Radiology, Northwestern Feinberg School of Medicine, Chicago, Illinois
2 shared publications- Delmarie M. Rivera Rodríguez
Feinberg School of Medicine, Northwestern University, Illinois, United States
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 135
Who should be considered for prostate artery embolization: revisiting the urologic guidelines based on results from over 300 patients with benign prostatic hyperplasia
Background: Prostate artery embolization (PAE) has emerged as a minimally invasive therapy which affords improvement in benign prostatic hyperplasia (BPH) symptoms and objective urinary parameters with a favorable adverse event (AE) profile. While PAE was recently included in the American Urological Association (AUA) Guidelines, guidance on its specific use-cases is limited. This study sought to answer remaining questions surrounding the safety and efficacy of PAE across different patient subpopulations where formal guidance for PAE is limited. Methods: Three hundred two patients with BPH underwent PAE. Key baseline characteristics were gathered. Patients were compared from baseline to follow-ups with regards to (1) objective parameters, including maximum urinary flow rate (Q max ), post-void residual (PVR), and prostate specific antigen (PSA); (2) prostate volume; (3) BPH symptoms, including International Prostate Symptom Score (IPSS), IPSS Quality-of-Life (IPSS-QoL), and BPH Impact Index (BPH-II); (4) sexual symptoms, including the International Index of Erectile function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function Short Form (MSHQ-EjD-SF); and (5) AEs. Additional sub-analyses were performed comparing the safety/efficacy of PAE across key sub-groups. Results: PAE afforded significant improvement ( p < 0.05) in each subjective/objective BPH parameter and sexual function score at nearly all follow-up points. Specifically, IPSS improved by 12.3–13.8 points (52.8–59.2%); IPSS-QoL by 2.3–2.8 points (47.9–58.3%); IIEF by 3.2–5.7 points (15.6–27.8%); PSA by 1.5–2.0 ng/mL (15.6–28.5%); and prostate volume by 16.9%. Twelve (4.0%) AEs were reported; no sexual/severe AEs were observed. PAE was safe and afforded significant improvement in subjective/objective BPH parameters in patients with: prostate volumes ≥ 80 mL; prior BPH surgery/intervention; higher medical comorbidity; pre-procedural catheter-dependent urinary retention; pre-procedural renal insufficiency; and pre-procedural hematuria. Conclusions: PAE improved subjective/objective BPH parameters and sexual function. Further, it safely afforded significant improvement in subjective/objective BPH parameters in specific contexts/scenarios where current guidance for PAE is limited, including patients with larger prostates, prior BPH intervention, higher medical comorbidity, urinary retention, renal insufficiency, and hematuria. Altogether, PAE can be performed safely and effectively in several real-world contexts in which formal guidance for PAE is limited, and where it may offer unique advantages compared to surgical therapies. Trial registration: Clinicaltrials.gov, NCT03052049. Registered 6 September 2017, https://clinicaltrials.gov/study/NCT03052049 ; Clinicaltrials.gov, NCT02026908. Registered 10 June 2019, https://cdn.clinicaltrials.gov/large-docs/08/NCT02026908/Prot_SAP_000.pdf .
- 23 October 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 135
Open AccessWho should be considered for prostate artery embolization: revisiting the urologic guidelines based on results from over 300 patients with benign prostatic hyperplasia
Background: Prostate artery embolization (PAE) has emerged as a minimally invasive therapy which affords improvement in benign prostatic hyperplasia (BPH) symptoms and objective urinary parameters with a favorable adverse event (AE) profile. While PAE was recently included in the American Urological Association (AUA) Guidelines, guidance on its specific use-cases is limited. This study sought to answer remaining questions surrounding the safety and efficacy of PAE across different patient subpopulations where formal guidance for PAE is limited. Methods: Three hundred two patients with BPH underwent PAE. Key baseline characteristics were gathered. Patients were compared from baseline to follow-ups with regards to (1) objective parameters, including maximum urinary flow rate (Q max ), post-void residual (PVR), and prostate specific antigen (PSA); (2) prostate volume; (3) BPH symptoms, including International Prostate Symptom Score (IPSS), IPSS Quality-of-Life (IPSS-QoL), and BPH Impact Index (BPH-II); (4) sexual symptoms, including the International Index of Erectile function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function Short Form (MSHQ-EjD-SF); and (5) AEs. Additional sub-analyses were performed comparing the safety/efficacy of PAE across key sub-groups. Results: PAE afforded significant improvement ( p < 0.05) in each subjective/objective BPH parameter and sexual function score at nearly all follow-up points. Specifically, IPSS improved by 12.3–13.8 points (52.8–59.2%); IPSS-QoL by 2.3–2.8 points (47.9–58.3%); IIEF by 3.2–5.7 points (15.6–27.8%); PSA by 1.5–2.0 ng/mL (15.6–28.5%); and prostate volume by 16.9%. Twelve (4.0%) AEs were reported; no sexual/severe AEs were observed. PAE was safe and afforded significant improvement in subjective/objective BPH parameters in patients with: prostate volumes ≥ 80 mL; prior BPH surgery/intervention; higher medical comorbidity; pre-procedural catheter-dependent urinary retention; pre-procedural renal insufficiency; and pre-procedural hematuria. Conclusions: PAE improved subjective/objective BPH parameters and sexual function. Further, it safely afforded significant improvement in subjective/objective BPH parameters in specific contexts/scenarios where current guidance for PAE is limited, including patients with larger prostates, prior BPH intervention, higher medical comorbidity, urinary retention, renal insufficiency, and hematuria. Altogether, PAE can be performed safely and effectively in several real-world contexts in which formal guidance for PAE is limited, and where it may offer unique advantages compared to surgical therapies. Trial registration: Clinicaltrials.gov, NCT03052049. Registered 6 September 2017, https://clinicaltrials.gov/study/NCT03052049 ; Clinicaltrials.gov, NCT02026908. Registered 10 June 2019, https://cdn.clinicaltrials.gov/large-docs/08/NCT02026908/Prot_SAP_000.pdf .
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240384
Exploring New Frontiers in Cryoablation and Immunotherapy Synergy
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240384
Exploring New Frontiers in Cryoablation and Immunotherapy Synergy
- Open Access
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (1) , 216-219
Prostate Artery Embolization for Benign Prostatic Hyperplasia
- 1 July 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (1) , 216-219
Open AccessProstate Artery Embolization for Benign Prostatic Hyperplasia
- Open Access
- 28 May 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (6) , 783-784
What Role Does PAE Play in the Management of Prostate Cancer?
- 28 May 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (6) , 783-784
Open AccessWhat Role Does PAE Play in the Management of Prostate Cancer?
- 2 February 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (5) , 744-750
Prostatic Artery Embolization in Patients with Refractory Lower Urinary Tract Symptoms after a Prior Minimally Invasive Surgical Treatment
- 2 February 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (5) , 744-750
Prostatic Artery Embolization in Patients with Refractory Lower Urinary Tract Symptoms after a Prior Minimally Invasive Surgical Treatment
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A30.1-A30
O-037 A first-in-human feasibility study to evaluate the safety of selective intra-arterial yttrium-90 microsphere treatment in patients with recurrent glioblastoma (FRONTIER trial)
Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor and virtually always recurs with no standard recurrent therapy. Median survival after recurrence is 7-12 months for clinical trial patients. Selective internal radiation therapy (SIRT) with Yttrium-90 (Y90) glass microspheres (TheraSphere™, Boston Scientific, Marlborough, MA) is an FDA approved standard treatment for hepatocellular carcinoma, and represents a promising strategy to treat regionally localized brain tumors. We present a clinical trial protocol for a novel recurrent glioblastoma treatment using Y90 microspheres modified to treat tumors in the brain. The goal of selectively delivering Y90 intra-arterially is to achieve higher tumoral absorbed doses while limiting non-target exposure. Design The primary objective is to evaluate the safety of Y90 microspheres treatment in patients with recurrent GBM following standard of care resection and chemo-radiotherapy. Target enrollment is 12 patients at 5 sites. Key inclusion criteria include: recurrent disease per RANO criteria between 1-5cm located in the non-dominant hemisphere in a non-eloquent region, accessible neurovascular anatomy for single intra-arterial treatment based on a diagnostic cerebral angiogram. Prior to enrollment, patients will undergo angiography and imaging will be reviewed by the trial steering committee to determine enrollment suitability. At treatment, Y90 microspheres are administered intra-arterially to deliver 40Gy ± 10% to the treatment volume. Post-administration Y90 PET and MRI images assess dose distribution and acute safety. Following overnight admission, visits occur weekly for 1 month and then monthly through 6 months. Primary endpoints include treatment-related limiting toxicities: grade 3-5 non-hematological toxicities, ≥ grade 3 CNS toxicity related to non-target embolization through 30 days post index procedure, including symptomatic cerebral ischemia or edema. Secondary endpoints include: treatment-related serious adverse events, change in post-treatment neurological function, technical success, objective response rate, progression-free survival, and overall survival. The study is registered with clinicaltrials.gov, number: NCT05303467. Disclosures S. Ansari: 2; C; Boston Scientific. D. Cantrell: None. M. Tate: 2; C; Boston Scientific. K. Dixit: None. R. Stupp: 2; C; Boston Scientific. R. Salem: 2; C; Boston Scientific. S. Mouli: 2; C; Boston Scientific.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A30.1-A30
Open AccessO-037 A first-in-human feasibility study to evaluate the safety of selective intra-arterial yttrium-90 microsphere treatment in patients with recurrent glioblastoma (FRONTIER trial)
Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor and virtually always recurs with no standard recurrent therapy. Median survival after recurrence is 7-12 months for clinical trial patients. Selective internal radiation therapy (SIRT) with Yttrium-90 (Y90) glass microspheres (TheraSphere™, Boston Scientific, Marlborough, MA) is an FDA approved standard treatment for hepatocellular carcinoma, and represents a promising strategy to treat regionally localized brain tumors. We present a clinical trial protocol for a novel recurrent glioblastoma treatment using Y90 microspheres modified to treat tumors in the brain. The goal of selectively delivering Y90 intra-arterially is to achieve higher tumoral absorbed doses while limiting non-target exposure. Design The primary objective is to evaluate the safety of Y90 microspheres treatment in patients with recurrent GBM following standard of care resection and chemo-radiotherapy. Target enrollment is 12 patients at 5 sites. Key inclusion criteria include: recurrent disease per RANO criteria between 1-5cm located in the non-dominant hemisphere in a non-eloquent region, accessible neurovascular anatomy for single intra-arterial treatment based on a diagnostic cerebral angiogram. Prior to enrollment, patients will undergo angiography and imaging will be reviewed by the trial steering committee to determine enrollment suitability. At treatment, Y90 microspheres are administered intra-arterially to deliver 40Gy ± 10% to the treatment volume. Post-administration Y90 PET and MRI images assess dose distribution and acute safety. Following overnight admission, visits occur weekly for 1 month and then monthly through 6 months. Primary endpoints include treatment-related limiting toxicities: grade 3-5 non-hematological toxicities, ≥ grade 3 CNS toxicity related to non-target embolization through 30 days post index procedure, including symptomatic cerebral ischemia or edema. Secondary endpoints include: treatment-related serious adverse events, change in post-treatment neurological function, technical success, objective response rate, progression-free survival, and overall survival. The study is registered with clinicaltrials.gov, number: NCT05303467. Disclosures S. Ansari: 2; C; Boston Scientific. D. Cantrell: None. M. Tate: 2; C; Boston Scientific. K. Dixit: None. R. Stupp: 2; C; Boston Scientific. R. Salem: 2; C; Boston Scientific. S. Mouli: 2; C; Boston Scientific.
- 20 December 2022
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 39 (06) , 562-570
Controversies in Prostate Artery Embolization: Future Best Practice
Prevalence of lower urinary tract symptoms secondary to benign prostatic hyperplasia is correlated with age. Men seeking treatment options with a low side effect profile often turn to prostate artery embolization (PAE). PAE continues to be refined with advanced tools and optimized techniques. Nonetheless, there exist controversies in terms of best practices for the management of lower urinary track symptoms (LUTS) with PAE. These controversies are essential for medical progress. Herein we suggest best practices moving forward based on currently available data. Given extensive safety data, we recommend PAE be considered alongside medical management and as a precursor to surgery. Given demonstrated efficacy across gland sizes, PAE can be performed in a single session, ideally in a hybrid angio-CT suite, without preoperative cross-sectional imaging. PAE should be initially performed with 300- to 500-μm size particles, and instead consider exploring other particles and sizes for repeat PAE. Finally, PAE can also be considered as first-line option for recurrent disease given the efficacy and excellent safety profile. This article is not meant to purport a dogma, but rather to serve as a guide to the experienced practitioner in challenging his or her own biases when performing PAE.
- 20 December 2022
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 39 (06) , 562-570
Controversies in Prostate Artery Embolization: Future Best Practice
Prevalence of lower urinary tract symptoms secondary to benign prostatic hyperplasia is correlated with age. Men seeking treatment options with a low side effect profile often turn to prostate artery embolization (PAE). PAE continues to be refined with advanced tools and optimized techniques. Nonetheless, there exist controversies in terms of best practices for the management of lower urinary track symptoms (LUTS) with PAE. These controversies are essential for medical progress. Herein we suggest best practices moving forward based on currently available data. Given extensive safety data, we recommend PAE be considered alongside medical management and as a precursor to surgery. Given demonstrated efficacy across gland sizes, PAE can be performed in a single session, ideally in a hybrid angio-CT suite, without preoperative cross-sectional imaging. PAE should be initially performed with 300- to 500-μm size particles, and instead consider exploring other particles and sizes for repeat PAE. Finally, PAE can also be considered as first-line option for recurrent disease given the efficacy and excellent safety profile. This article is not meant to purport a dogma, but rather to serve as a guide to the experienced practitioner in challenging his or her own biases when performing PAE.
- 14 November 2022
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 58 (1) , 232-233
Editorial for “Diffusion‐Weighted Imaging of the Abdomen: Correction for Gradient Nonlinearity Bias in Apparent Diffusion Coefficient”
- 14 November 2022
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 58 (1) , 232-233
Editorial for “Diffusion‐Weighted Imaging of the Abdomen: Correction for Gradient Nonlinearity Bias in Apparent Diffusion Coefficient”